Compare SSD & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSD | IMVT |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.0B |
| IPO Year | 1996 | 2019 |
| Metric | SSD | IMVT |
|---|---|---|
| Price | $188.89 | $39.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $214.75 | $33.00 |
| AVG Volume (30 Days) | 330.8K | ★ 1.4M |
| Earning Date | 04-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 8.42 | N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $2,332,808,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | $88.37 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $156.32 | $14.32 |
| 52 Week High | $213.49 | $41.23 |
| Indicator | SSD | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 63.51 |
| Support Level | $162.84 | $25.13 |
| Resistance Level | $197.71 | N/A |
| Average True Range (ATR) | 4.71 | 1.37 |
| MACD | -2.09 | -0.20 |
| Stochastic Oscillator | 11.55 | 57.53 |
Simpson Manufacturing Co Inc designs, manufactures, and markets systems and products to make buildings and structures safe and secure. It produces wood construction products, including connectors, truss plates, fastening systems, fasteners, and shearwalls, as well as concrete construction products such as adhesives, specialty chemicals, mechanical anchors, powder actuated tools, and fiber reinforcing materials. The company serves residential, industrial, commercial, and infrastructure construction, remodeling, and do-it-yourself markets, operating exclusively in the building products industry. It has three regional segments: North America, Europe, and Asia/Pacific. The majority of its revenue comes from wood products.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.